Incyte Reports the US FDA's Acceptance of NDA for Parsaclisib to Treat R/R Non-Hodgkin Lymphomas
Shots:
- The submission is based on P-II studies i.e., CITADEL-203/204/205 that evaluate parsaclisib in patients with r/r FL, MZL & MCL. The anticipated PDUFA date for parsaclisib in adult patients with r/r FL is Aug 30, 2022.
- The results from the studies showed that Parsaclisib was generally well-tolerated with a manageable safety profile
- The FDA grants the priority review of parsaclisib for r/r MZL who have received at least one prior anti-CD20-based regimen & for MCL who have received at least one prior therapy & the designation shortens the review period by 4mos. as compared to standard review. The anticipated PDUFA date is April 30, 2022 to / article
Ref: Incyte | Image: Incyte
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com